Nitroglycerin attenuates vasoconstriction of HBOC-201 during hemorrhagic shock resuscitation

Resuscitation

Volumn 81, Issue 4, 2010, Pages 481-487

  Katz, Laurence M ^a   Manning, James E ^a   McCurdy, Shane ^a   Sproule, Charles ^a   McGwin Jr , Gerald ^b   Moon Massat, Paula ^c   Cairns, Charles B ^a   Freilich, Daniel ^c,d,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Hemoglobin Based Oxygen Carrier; Hemorrhage; Nitroglycerin; Vasoconstriction

Indexed keywords

GLYCERYL TRINITRATE; LACTIC ACID; METHEMOGLOBIN; POLYMERIZED HEMOGLOBIN; RINGER LACTATE SOLUTION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEMORRHAGIC SHOCK; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SWINE; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; BLOOD SUBSTITUTES; HEMOGLOBINS; MALE; NITROGLYCERIN; RESUSCITATION; SHOCK, HEMORRHAGIC; SWINE; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 77649338802     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2009.12.015     Document Type: Article

References (40)

1. Natanson C., Kern S.J., Lurie P., Banks S.M., and Wolfe S.M. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299 (2008) 2304-2312
2. Food and Drug Administration Blood Product Advisory Committee 88th Meeting, December 14, 2006, http://www.fda.gov/OHRMS/DOCKETS/ac/cber2006.html#BloodProducts; 2006 [accessed 25.09.09].
3. Minneci P.C., Deans K.J., Shiva S., et al. Nitrite reductase activity of hemoglobin as a systemic nitric oxide generator mechanism to detoxify plasma hemoglobin produced during hemolysis. Am J Physiol Heart Circ Physiol 295 (2008) H743-H754
4. Kavdia M., Tsoukias N.M., and Popel A.S. Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. Am J Physiol 282 (2002) H2245-H2253
5. Huellner M.W., Schrepfer S., Weyand M., et al. Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins. FASEB J 22 (2008) 2561-2568
6. Marsh N., and Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol 27 (2000) 313-319
7. Rude R.E., Muller J.E., and Braunwald E. Efforts to limit the size of myocardial infarcts. Ann Intern Med 95 (1981) 736-761
8. Pearce L.B., and Gawryl M.S. The pharmacology of tissue oxygenation by biopure's hemoglobin-based oxygen carrier Hemopure (HBOC-201). Adv Exp Med Biol 530 (2003) 261-270
9. Standl T. Haemoglobin-based erythrocyte transfusion substitutes. Expert Opin Biol Ther 1 (2001) 831-843
10. Pearce L.G.M. Overview of preclinical and clinical efficacy of Biopure's HBOCs vol. 2 (1998), Krager Landes Systems, Basel, Switzerland
11. McNiff E.F., Yacobi A., Young-Chang F.M., Golden L.H., Goldfarb A., and Fung H.L. Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. J Pharm Sci 70 (1981) 1054-1058
12. Katz L.M., Manning J.E., McCurdy S., et al. HBOC-201 improves survival in a swine model of hemorrhagic shock and liver injury. Resuscitation 54 (2002) 77-87
13. Manning J.E., Katz L.M., Brownstein M.R., Pearce L.B., Gawryl M.S., and Baker C.C. Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Carolina Resuscitation Research Group. Shock 13 (2000) 152-159
14. Shearburn III E.W., Craig W.D., Maitland C.L., Howard P.L., McCoy S., and Drucker W.R. Hemodynamic and metabolic alterations in peripheral tissue during hemorrhagic shock. Am Surg 41 (1975) 696-703
15. Ali S.Z., Bracht H., Krejci V., et al. The immediate and sustained effects of volume challenge on regional blood flows in pigs. Anesth Analg 106 (2008) 595-600
16. Waxman K., Tremper K.K., and Mason G.R. Blood and plasma substitutes-plasma expansion and oxygen transport properties. West J Med 143 (1985) 202-206
17. Salmon J.B., and Mythen M.G. Pharmacology and physiology of colloids. Blood Rev 7 (1993) 114-120
18. Doherty D.H., Doyle M.P., Curry S.R., et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 16 (1998) 672-676
19. Patel R.P. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med 28 (2000) 1518-1525
20. Thompson A., McGarry A.E., Valeri C.R., and Lieberthal W. Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J Appl Physiol 77 (1994) 2348-2354
21. Doyle M.P., and Hoekstra J.W. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem 14 (1981) 351-358
22. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
23. Yu B., Raher M.J., Volpato G.P., Bloch K.D., Ichinose F., and Zapol W.M. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 117 (2008) 1982-1990
24. Bilello K., Schultz S., Powell C., Jaffin J., Cole F., and Malcolm D. Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with anti-hypertensive agents. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 819-825
25. Rioux F., Drapeau G., and Marceau F. Recombinant human hemoglobin (rHb1.1) selectively inhibits vasorelaxation elicited by nitric oxide donors in rabbit isolated aortic rings. J Cardiovasc Pharmacol 25 (1995) 587-594
26. Erhart S.M., Cole D.J., Patel P.M., Drummond J.C., and Burhop K.E. Effect of alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) on the potency of sodium nitroprusside and nitroglycerine to decrease blood pressure in rats: a dose-response study. Artif Cells Blood Substit Immobil Biotechnol 28 (2000) 385-396
27. Troncy E., Francoeur M., Salazkin I., et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine. Br J Anaesth 79 (1997) 631-640
28. Quezado Z.M., Natanson C., Karzai W., et al. Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis. J Appl Physiol 84 (1998) 107-115
29. Groves P.H., Lewis M.J., Cheadle H.A., and Penny W.J. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation 87 (1993) 590-597
30. Zhang J., Somers M., and Cobb F.R. Heterogeneous effects of nitroglycerin on the conductance and resistance coronary arterial vasculature. Am J Physiol 264 (1993) H1960-H1968
31. Feelisch M., and Noack E. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur J Pharmacol 142 (1987) 465-469
32. Wang P., Ba Z.F., and Chaudry I.H. Endothelial cell dysfunction occurs very early following trauma-hemorrhage and persists despite fluid resuscitation. Am J Physiol 265 (1993) H973-H979
33. Linberg R., Conover C.D., Shum K.L., and Shorr R.G. Hemoglobin based oxygen carriers: how much methemoglobin is too much?. Artif Cells Blood Substit Immobil Biotechnol 26 (1998) 133-148
34. Brower V. Fast tracking drugs to patients. Drug approval agencies are frequently criticised for either being too slow or too fast. EMBO Rep 3 (2002) 14-16
35. Knudson M.M., Lee S., Erickson V., Morabito D., Derugin N., and Manley G.T. Tissue oxygen monitoring during hemorrhagic shock and resuscitation: a comparison of lactated Ringer's solution, hypertonic saline dextran, and HBOC-201. J Trauma 54 (2003) 242-252
36. Kelm M., Feelisch M., Deussen A., Strauer B.E., and Schrader J. Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc Res 25 (1991) 831-836
37. Proctor K.G. Blood substitutes and experimental models of trauma. J Trauma 54 (2003) S106-S109
38. Moore F.A., McKinley B.A., and Moore E.E. The next generation in shock resuscitation. Lancet 363 (2004) 1988-1996
39. Jost S., Reil G., Knop I., et al. Coronary vasodilation with nitrocompounds-is there a maximum?. Z Kardiol 78 (1989) 38-40
40. Noonan P.K., Williams R.L., and Benet L.Z. Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. J Pharmacokinet Biopharm 13 (1985) 143-157